Island Pharmaceuticals Company Description

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America.

Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases.

The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Phase 2a/b clinical study for ISLA-101.

Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.

Island Pharmaceuticals Limited

Country	Australia
Founded	2017
Industry	Biotechnology
Sector	Healthcare
CEO	David Foster

Contact Details

Address: 697 Burke Road Camberwell, 3124 Australia
Phone	61 3 7036 7675
Website	islandpharmaceuticals.com

Stock Details

Ticker Symbol	ILA
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000138869
SIC Code	2834

Key Executives

Name	Position
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D.	MD, Chief Executive Officer, President and Executive Director
Phillip Randolph Lynch	Executive Chair
Cameron Peter Jones C.A.	Chief Financial Officer and Company Secretary